Company profile for Benitec Biopharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for the goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. We believe our technology has the potential to provide a “one shot” cure for a wide range of diseases that are currently addressed by strict ongoing treatment regimens o...
Benitec is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for the goal of providing sustained, long-lasting silencing of disease-causing genes from a single administration. We believe our technology has the potential to provide a “one shot” cure for a wide range of diseases that are currently addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. At Benitec we are using this technology, called DNA-directed RNA interference, or ddRNAi, to develop product candidates in chronic.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3940 Trust Way Hayward, CA. 94545
Telephone
Telephone
+61 (0)3 8692-7222
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/05/3182031/0/en/Benitec-Biopharma-Inc-Announces-Proposed-Public-Offering.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3178822/0/en/Benitec-Biopharma-to-Provide-Phase-1b-2a-Clinical-Study-Update-for-BB-301-in-Oculopharyngeal-Muscular-Dystrophy.html

GLOBENEWSWIRE
02 Nov 2025

https://www.globenewswire.com/news-release/2025/09/22/3154295/0/en/Benitec-Biopharma-Releases-Full-Year-2025-Financial-Results-and-Provides-Operational-Update.html

GLOBENEWSWIRE
22 Sep 2025

https://www.globenewswire.com/news-release/2025/07/09/3112510/0/en/Benitec-Biopharma-Provides-Operational-Updates.html

GLOBENEWSWIRE
09 Jul 2025

https://www.globenewswire.com/news-release/2025/05/14/3080988/0/en/Benitec-Biopharma-Releases-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
14 May 2025

https://www.globenewswire.com/news-release/2025/03/25/3048686/0/en/Benitec-Biopharma-Inc-Announces-Pricing-of-30-Million-Common-Stock-Offering.html

GLOBENEWSWIRE
25 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty